Skip to main content

Advertisement

SpringerLink
Log in

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis

Comment on “Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis”

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Biver E, Calmy A, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C (2019) Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int. https://doi.org/10.1007/s00198-018-4794-0

  2. Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 29:595–613

    Article  CAS  PubMed  Google Scholar 

  3. Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S (2017) Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr 75:211–218

    Article  CAS  PubMed  Google Scholar 

  4. Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS (2017) Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>. HIV Clin Trials 18:135–140

    Article  CAS  PubMed  Google Scholar 

  5. Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS (2017) Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in hiv-infected, virologically suppressed adults. J Acquir Immune Defic Syndr 75:226–231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M (2018) Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV 5:e23–e34

    Article  PubMed  Google Scholar 

  7. Hill A, Hughes SL, Gotham D, Pozniak AL (2018) Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad 4:72–79

    PubMed  PubMed Central  Google Scholar 

  8. Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 391:839–849

    Article  CAS  PubMed  Google Scholar 

  9. McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, Angelis K, Wynne B, Vandermeulen K, Gartland M, Cupo M, Aboud M (2018) Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. Aids 32:477–485

    CAS  PubMed  Google Scholar 

  10. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T (2015) Less bone loss with maraviroc- versus tenofovir-containing antiretroviral therapy in the AIDS clinical trials group A5303 study. Clin Infect Dis 61:1179–1188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d’Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D’Avino A, Foca E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A (2018) Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. https://doi.org/10.1093/jac/dky123

  12. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K (2019) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 393:143–155

    Article  CAS  PubMed  Google Scholar 

  13. Moran CA, Weitzmann MN, Ofotokun I (2016) The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 11:333–342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dube MP, Murphy RL, Stein JH, McComsey GA (2015) Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 212:1241–1249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MVZ Karlsplatz, HIV Research and Clinical Care Center, 80335, Munich, Germany

    S. Noe & H. Jaeger

  2. MUC Research, 80335, Munich, Germany

    E. Wolf

Authors
  1. S. Noe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Jaeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Noe.

Ethics declarations

Conflicts of interests

Sebastian Noe, Hans Jaeger, and Eva Wolf have received honoraria and/or travel grants from Gilead Sciences, GlaxoSmithKline, Hexal, Janssen, MERCK SHARP & DOHME, and ViiV Healthcare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noe, S., Jaeger, H. & Wolf, E. Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Osteoporos Int 30, 1705–1706 (2019). https://doi.org/10.1007/s00198-019-05024-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-05024-4

Search

Navigation